Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

Favorable outcomes of NPM1^mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

Blood Cancer J. 2023 Aug 22;13(1):128. doi: 10.1038/s41408-023-00898-4.

I Khan^#^{1

2}, A Kaempf^#³, S Raghuwanshi^#¹, M Chesnokov⁴, X Zhang¹, Z Wang^{5

6}, A Domling⁵, J W Tyner³, C Camacho⁷, A L Gartel⁸

¹ University of Illinois at Chicago, Department of Medicine, Chicago, IL, USA.
² Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
³ OHSU Knight Cancer Institute, School of Medicine, Portland, OR, USA.
⁴ Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.
⁵ The Czech Advanced Technology and Research Institute (CATRIN) of Palacký University, Olomouc, Czech Republic.
⁶ University of Groningen, Groningen, Netherlands.
⁷ Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA, USA.
⁸ University of Illinois at Chicago, Department of Medicine, Chicago, IL, USA. agartel@uic.edu.

^# Contributed equally.

No abstract available